AtaiBeckley Inc. 4

Chief Medical Officer Craig Kevin James had all his AtaiBeckley common stock, stock options (totaling roughly 1.82 million underlying shares), and 150,000 RSUs automatically cancelled and cashed out at the $6.75 per share merger price plus CVRs in connection with Eli Lilly’s acquisition of AtaiBeckley Inc.

On September 11, 2026, in connection with the closing of Eli Lilly’s acquisition of AtaiBeckley Inc., all of Chief Medical Officer Craig Kevin James’s equity in AtaiBeckley was cashed out and cancelled: 8,437 shares of common stock and a series of vested and unvested stock options covering 10,000 shares at $5.54, 50,400 shares at $2.86, 28,608 shares at $1.18, 372,701 shares at $1.84, 673,808 shares at $1.50, and 675,000 shares at $3.76 were terminated in exchange for cash consideration equal to the in‑the‑money amount based on the $6.75 per share merger price plus one contingent value right (CVR) per underlying share, and 150,000 RSUs were likewise cancelled for cash based on $6.75 per unit plus one CVR per unit. These transactions reflect an automatic conversion of existing equity under the merger agreement rather than discretionary open‑market trading, and left James with no remaining AtaiBeckley equity holdings as the company became a wholly owned subsidiary of Eli Lilly.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036390

Alert Tier

6